亚砷酸注射液治疗难治性B细胞非霍奇金淋巴瘤.PDF

200 7 13 7 Chinese C lin ical Oncology, Jul. 200 , Vo.l 13, No. 7 635 B 1 210002 南京 解放军八一医院全军肿瘤中心内科 杨宁蓉, 秦叔逵 , 王 琳 : (, As O ) B ( NH L) 2 3 : 11 B NHL , 9, 3, 4 , A s O 10mg /d, 2 3 d ~ d d ~ d , 2WHO, : 11, CR 2, PR 3, 1 15 1 21 ( CR+ PR) 4545% : As O B 2 3 NHL, , /; ; B : R7334 : A : 1009- 0460( 200 ) 07- 0635- 02 Arsenious oxide in the treatment of patientswith recurrent and refractory B cellnonHodgkins lymphoma YANGN ingrong, QIN Shukui, WANG L in. D epartm ent of Oncology, Oncology Center of LA, 1H osp italof LA, N anj ing 210002, China Corresp onding author: QIN Shukui, Email: qinsk@ csco. org. cn Abstract Objective:To observe the effects and safety of arsen ious oxide adm inistration in refractory B cellNHL.M ethods: 11 patients of m ales and 3 fem alesw ith refractory B cellNHL are observed in th is research (m ed ian age was 4 ), all of them are re th th treated cases. A rsen ious oxide 10m g/d infusion, from the first to 15 or the first to 21 day, repeated every 3 week. Shortterm thera peutic effects and adverse reactionsw ere evaluated accord ing to the standard of WHO. Results: The total response rate w as 4545% w ith 2 cases of CR and 3 cases of PR. Leukocytopen ia, hepatorenal dysfunction, and abdom inal distention were m ajor side reactions. onclusion: Arsenious oxide is effective in the treatm ent of refractory B cell NHL according to our prelmi inary observation. KeyW ords Arsenious oxide/A rsen ictrioxide; NonH odgkins lym phom a; Bcell lymphom a ( NHL )